Close

Aurinia Pharmaceuticals (AUPH) Says Voclosporin Achieves Primary, Secondary Endpoints in Phase IIb Study for LN

September 29, 2016 4:56 PM EDT Send to a Friend
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login